Improvements in tumor targeting, survivorship, and chemoprevention pioneered by tamoxifen. A personal perspective.

نویسندگان

  • V Craig Jordan
  • Alfred G Knudson
چکیده

Twenty years ago, antiestrogen therapy with tamoxifen played only a secondary role in breast cancer care. All hopes to cure metastatic breast cancer were still pinned on either the discovery of new cytotoxic drugs or a dose-dense combination of available cytotoxic drugs with bone marrow transplantation. A similar strategy with combination chemotherapy was employed as an adjuvant for primary breast cancer. Simply stated, the goal was to kill the cancer with nonspecific cytotoxic drugs while keeping the patient alive with supportive care. However, medical research does not travel in straight lines, and an alternative approach emerged to solve the problem of controlling tumor growth with minimal side effects: targeted therapy. The approach of using long-term antihormone therapy to control early-stage breast cancer growth would revolutionize cancer care by targeting the tumor estrogen receptor (ER). The success of the strategy would contribute to a decrease in the national mortality figures for breast cancer. More importantly, translational research that targeted the tumor ER with a range of new antiestrogenic drugs would presage the current fashion of blocking survival pathways for the tumor by developing novel targeted treatments. But a surprise was in store when the pharmacology of "antiestrogens" was studied in detail: The nonsteroidal "antiestrogens" are selective ER modulators--ie, they are antiestrogens in the breast, estrogens in the bone--and they lower circulating cholesterol levels. This knowledge would establish a practical approach to breast cancer chemoprevention for women at high risk (tamoxifen) and low risk (raloxifene).

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Improvements in Tumor Targeting, Survivorship, and Chemoprevention Pioneered by Tamoxifen

Twenty years ago, antiestrogen therapy with tamoxifen played only a secondary role in breast cancer care. All hopes to cure metastatic breast cancer were still pinned on either the discovery of new cytotoxic drugs or a dose-dense combination of available cytotoxic drugs with bone marrow transplantation. A similar strategy with combination chemotherapy was employed as an adjuvant for primary bre...

متن کامل

Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer.

Tamoxifen is an unlikely pioneering medicine in medical oncology. Nevertheless, the medicine has continued to surprise us, perform, and save lives for the past 40 years. Unlike any other medicine in oncology, it is used to treat all stages of breast cancer, ductal carcinoma in situ, and male breast cancer and pioneered the use of chemoprevention by reducing the incidence of breast cancer in wom...

متن کامل

Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women.

BACKGROUND Tamoxifen can reduce the risk of developing invasive estrogen receptor-positive breast cancer by 49%, but it is unknown how many women in the United States are taking tamoxifen for primary prevention of breast cancer. METHODS Data from the years 2000 and 2005 National Health Interview Surveys were analyzed to estimate the prevalence of tamoxifen use among U.S. women for primary che...

متن کامل

بررسی بیوانفورماتیکی میانکنش بین میکرو RNAها با ژن‌های دخیل در عود مجدد سرطان پستان درمان شده با تاموکسیفن

Background and Objective: Tamoxifen is the most commonly used treatment for the patients with breast cancer called ER +, which prevents the expression of genes that are effective in the growth and proliferation of cancer cells by estrogen. Resistant to Tamoxifen is a major clinical problem in breast cancer treatment. In recent studies, the role of microRNAs in tamoxifen resistance has been rais...

متن کامل

The role of tumor grade, demographics and psychological factors in Cancer survivorship

Introduction: The aim of this study was to predict cancer survival according to the role of demographic determinants, psychological factors and tumor grade. Methods: In this cross-sectional retrospective study, 350 patients with blood, breast, prostate, lung, stomach and colon cancers (173 patients with cancer survival for more than 2 years and 177 patients with cancer survival for 2 years o...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Oncology

دوره 20 6  شماره 

صفحات  -

تاریخ انتشار 2006